The Ratio of MI to DCI and Its Impact in the Treatment of Polycystic Ovary Syndrome: Experimental and Literature Evidences

International Society of Gynecological Endocrinology Series

Volumn , Issue , 2016, Pages 103-109

  Facchinetti, Fabio ^a   Dante, Giulia ^a   Neri, Isabella ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Follicular Fluid; Gestational Diabetes Mellitus; Oocyte Maturation; Polycystic Ovary Syndrome; Sperm Cell

Indexed keywords

EID: 85016722699     PISSN: 21978735     EISSN: 21978743     Source Type: Book Series    
DOI: 10.1007/978-3-319-23865-4_13     Document Type: Chapter

References (21)

1. Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18:774–800
2. Murthy PPN (2006) Structure and nomenclature of inositol phosphates, phosphoinositides, and glycosylphosphatidylinositols. In: Lahiri Majumder A, Biswas BB (eds) Biology of inosi-tols and phosphoinositides. Springer, New York, pp 1–19
3. Clements RS Jr, Darnell B (1980) Myo-inositol content of common foods: development of a high-myo-inositol diet. Am J Clin Nutr 33(9):1954–1967
4. Larner J, Huang LC, Tang G, Suzuki S, Schwartz CFW, Romero G, Roulidis Z, Zeller K, Shen TY, Oswald AS, Luttrell L (1988) Insulin mediators: structure and formation. Cold Spring Harb Symp Quant Biol 53(Pt 2):965–971
5. Sun TH, Heimark DB, Nguygen T, Nadler JL, Larner J (2002) Both myoinositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun 293:1092–1098
6. Heimark D, McAllister J, Larner J (2014) Decreased myo-inositol to chiro-inositol (m/c) ratios and increased m/c epimerase activity in pcos theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J 61:111–117
7. Pak Y, Huang LC, Lilley KJ, Larner J (1992) In vivo conversion of [3H] myoinositol to [3H] chiroinositol in rat tissues. J Biol Chem 267:16904–16910
8. Carlomagno G, De Grazia S, Unfer V, Manna F (2012) Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use. Expert Opin Drug Deliv 9(3):267–271. doi: 10.1 517/17425247.2012.662953
9. De Grazia S, Carlomagno G, Unfer V, Cavalli P (2012) Myo-inositol soft gel capsules may prevent the risk of coffee-induced neural tube defects. Expert Opin Drug Deliv 9(9):1033– 1039. doi:10.1517/17425247.2012.701616, Epub 2012 Jul 5
10. Unfer V, Carlomagno G, Papaleo E, Vailati S, Candiani M, Baillargeon JP (2014) Hyperinsulinemia alters myoinositol to d-chiroinositol ratio in the follicular fluid of patients with PCOS. Reprod Sci 21:854–858
11. Carlomagno G, Unfer V, Roseff S (2011) The D-chiro-inositol paradox in the ovary. Fertil Steril 95:2515–2516
12. Unfer V, Carlomagno G, Rizzo P, Raffone E, Roseff S (2011) Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci 15:452–457
13. Arya BK, Haq AU, Chaudhury K (2012) Oocyte quality reflected by follicular fluid analysis in polycystic ovary syndrome (PCOS): a hypothesis based on intermediates of energy metabolism. Med Hypotheses 78:475–478
14. Nordio M, Proietti E (2012) The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci 16:575–581
15. Minozzi M, Nordio M, Pajalich R (2013) The combined therapy myo-inositol plus D-chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci 17:537–540
16. Bevilacqua A, Carlomagno G, Gerli S, Montanino Oliva M, Devroey P, Lanzone A, Soulange C, Facchinetti F, Di Renzo GC, Bizzarri M, Hod M, Cavalli P, D’Anna R, Benvenga S, Chiu TT, Kamenov ZA (2015) Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in Obstetrics and Gynecology – assisted reproduction technology. Gynecol Endocrinol. doi:10.3109/09513590.2015.1006616
17. Chiu TT, Tam PP (1992) A correlation of the outcome of clinical in vitro fertilization with the inositol content and embryotrophic properties of human serum. J Assist Reprod Genet 9:524–530
18. Chiu TT, Rogers MS, Law EL, Briton-Jones CM, Cheung LP, Haines CJ (2002) Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod 17:1591–1596
19. Colazingari S, Fiorenza MT, Carlomagno G, Najjar R, Bevilacqua A (2014) Improvement of mouse embryo quality by myo-inositol supplementation of IVF media. J Assist Reprod Genet 31:463–469
20. Ma X, Fan L, Meng Y, Hou Z, Mao YD, Wang W, Ding W, Liu JY (2007) Proteomic analysis of human ovaries from normal and polycystic ovarian syndrome. Mol Hum Reprod 13:527–535
21. Chaudhary K, Babu KN, Joshi VN, Srivastava S, Chakravarty BN (2011) NMR-based metabolomics reveals differently expressed metabolites in follicular fluid of PCOS women: potential biomarkers for good quality oocyte? Hum Reprod 26:i226–i246